Disclosure LL: research funds from clinical studies participations AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai Exelixis, Debiopharm International SA, Hoffmann, La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD, Novartis, Pfizer, Roche and Buran. Fees for participation as a speaker at conferences/congresses or as a scientific consultant for advisory boards (AccMed, AstraZeneca, Bayer, Merck-Serono, MSD, Neutron Therapeutics). PGC: at INT, Prof Casali Unit received funds from: Advenchen Laboratories, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc, Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer, PharmaMar Advenchen Laboratories, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc, Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer and PharmaMar. AMF: received funds from: Advenchen Laboratories, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc, Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer, PharmaMar Advenchen Laboratories, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc, Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer, PharmaMar. All other authors have declared no conflicts of interest.